Current Report Filing (8-k)
April 21 2021 - 7:07AM
Edgar (US Regulatory)
0001429560
false
0001429560
2021-04-21
2021-04-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 21, 2021
TREVENA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36193
|
|
26-1469215
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
(Address of principal executive offices
and zip code)
(610) 354-8840
(Registrant’s telephone number, including
area code)
n/a
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
TRVN
|
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure
|
On April 21, 2021, Trevena, Inc. (the “Company”)
updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit
99.1.
The information set forth on this Item 7.01 and
furnished hereto as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly
set forth by specific reference in any such filing.
On April 21, 2021, the Company issued a press
release announcing that TRV027, the Company’s investigational, novel AT1 receptor selective agonist, has been selected
for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients being conducted and funded as part
of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia). REMAP-CAP is financially
supported by an array of governments and research organizations worldwide. A copy of the press release is filed as Exhibit 99.2 to this
Current Report on Form 8-K and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TREVENA, INC.
|
|
|
Date: April 21, 2021
|
By:
|
/s/ Barry Shin
|
|
|
Barry Shin
|
|
|
Senior Vice President &Chief Financial Officer
|
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Sep 2023 to Sep 2024